Published in Cancer Cell on April 01, 2008
Structure of a clade C HIV-1 gp120 bound to CD4 and CD4-induced antibody reveals anti-CD4 polyreactivity. Nat Struct Mol Biol (2010) 1.77
Distribution of resting and ligand-bound ErbB1 and ErbB2 receptor tyrosine kinases in living cells using number and brightness analysis. Proc Natl Acad Sci U S A (2010) 1.45
Targeted therapy for malignant glioma patients: lessons learned and the road ahead. Neurotherapeutics (2009) 1.22
Membrane rafts and caveolae in cardiovascular signaling. Curr Opin Nephrol Hypertens (2009) 1.19
A biparatopic anti-EGFR nanobody efficiently inhibits solid tumour growth. Int J Cancer (2011) 1.16
Efalizumab binding to the LFA-1 alphaL I domain blocks ICAM-1 binding via steric hindrance. Proc Natl Acad Sci U S A (2009) 1.13
Interaction of antibodies with ErbB receptor extracellular regions. Exp Cell Res (2008) 1.13
Antibodies specifically targeting a locally misfolded region of tumor associated EGFR. Proc Natl Acad Sci U S A (2009) 1.07
Stable RAGE-heparan sulfate complexes are essential for signal transduction. ACS Chem Biol (2013) 1.07
Recent advances of novel targeted therapy in non-small cell lung cancer. J Hematol Oncol (2009) 1.06
Microcrystallography using single-bounce monocapillary optics. J Synchrotron Radiat (2010) 1.03
Structural evaluation of EGFR inhibition mechanisms for nanobodies/VHH domains. Structure (2013) 1.01
Bispecific designed ankyrin repeat proteins (DARPins) targeting epidermal growth factor receptor inhibit A431 cell proliferation and receptor recycling. J Biol Chem (2011) 1.00
Emerging antibody combinations in oncology. MAbs (2011) 0.94
Anti-HER3 domain 1 and 3 antibodies reduce tumor growth by hindering HER2/HER3 dimerization and AKT-induced MDM2, XIAP, and FoxO1 phosphorylation. Neoplasia (2013) 0.93
A fibronectin scaffold approach to bispecific inhibitors of epidermal growth factor receptor and insulin-like growth factor-I receptor. MAbs (2011) 0.92
The contribution of cetuximab in the treatment of recurrent and/or metastatic head and neck cancer. Biologics (2010) 0.91
EGFR/HER-targeted therapeutics in ovarian cancer. Future Med Chem (2012) 0.90
A molecular view of anti-ErbB monoclonal antibody therapy. Cancer Cell (2008) 0.87
Peptide vaccines and peptidomimetics of EGFR (HER-1) ligand binding domain inhibit cancer cell growth in vitro and in vivo. J Immunol (2013) 0.87
Design and development of masked therapeutic antibodies to limit off-target effects: application to anti-EGFR antibodies. Cancer Biol Ther (2009) 0.86
Sensitivity and resistance to EGF-R inhibitors: approaches to enhance the efficacy of EGF-R antibodies. MAbs (2009) 0.83
Toward a magic or imaginary bullet? Ligands for drug targeting to cancer cells: principles, hopes, and challenges. Int J Nanomedicine (2015) 0.82
Safety and efficacy of panitumumab therapy after metastatic colorectal cancer progression with cetuximab: Experience at a single Japanese institution. Oncol Lett (2013) 0.82
CCN2 inhibits lung cancer metastasis through promoting DAPK-dependent anoikis and inducing EGFR degradation. Cell Death Differ (2012) 0.82
Receptor-tyrosine-kinase-targeted therapies for head and neck cancer. J Signal Transduct (2011) 0.82
Combining anti-ERBB3 antibodies specific for domain I and domain III enhances the anti-tumor activity over the individual monoclonal antibodies. PLoS One (2014) 0.81
Enhanced dimerization drives ligand-independent activity of mutant epidermal growth factor receptor in lung cancer. Mol Biol Cell (2015) 0.81
Protein design of IgG/TCR chimeras for the co-expression of Fab-like moieties within bispecific antibodies. MAbs (2015) 0.79
Molecular dynamics simulations of transitions for ECD epidermal growth factor receptors show key differences between human and drosophila forms of the receptors. Proteins (2013) 0.78
Efficient blockade of Akt signaling is a determinant factor to overcome resistance to matuzumab. Mol Cancer (2011) 0.78
Treatment of recurrent metastatic head and neck cancer: focus on cetuximab. Clin Med Insights Ear Nose Throat (2012) 0.78
Humoral immune responses to EGFR-derived peptides predict progression-free and overall survival of non-small cell lung cancer patients receiving gefitinib. PLoS One (2014) 0.76
Affinity Maturation of an Epidermal Growth Factor Receptor Targeting Human Monoclonal Antibody ER414 by CDR Mutation. Immune Netw (2012) 0.76
IgE immunotherapy against cancer. Curr Top Microbiol Immunol (2015) 0.75
Magic bullets from llamas. Structure (2013) 0.75
Balancing Selectivity and Efficacy of Bispecific Epidermal Growth Factor Receptor (EGFR) × c-MET Antibodies and Antibody-Drug Conjugates. J Biol Chem (2016) 0.75
MR signal amplification for imaging of the mutant EGF receptor in orthotopic human glioma model. Mol Imaging Biol (2013) 0.75
Antibodies Targeting Closely Adjacent or Minimally Overlapping Epitopes Can Displace One Another. PLoS One (2017) 0.75
Computational Design of a Specific Heavy Chain/κ Light Chain Interface for Expressing Fully IgG Bispecific Antibodies. Protein Sci (2017) 0.75
A phase I pharmacokinetic study of matuzumab in combination with paclitaxel in patients with EGFR-expressing advanced non-small cell lung cancer. Invest New Drugs (2012) 0.75
Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr (2004) 227.01
The CCP4 suite: programs for protein crystallography. Acta Crystallogr D Biol Crystallogr (1994) 187.88
Crystallography & NMR system: A new software suite for macromolecular structure determination. Acta Crystallogr D Biol Crystallogr (1998) 169.28
Cell signaling by receptor tyrosine kinases. Cell (2000) 18.16
Shape complementarity at protein/protein interfaces. J Mol Biol (1993) 10.40
An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor. Cell (2006) 10.28
Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature (2003) 6.78
Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell (2004) 6.12
Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains. Cell (2002) 5.64
An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors. Mol Cell (2003) 5.06
Crystal structure of a truncated epidermal growth factor receptor extracellular domain bound to transforming growth factor alpha. Cell (2002) 4.92
Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. Cancer Cell (2005) 4.73
EGF activates its receptor by removing interactions that autoinhibit ectodomain dimerization. Mol Cell (2003) 4.23
Epidermal growth factor receptor targeting in cancer. Semin Oncol (2006) 3.84
Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells. Cancer Res (2001) 3.62
Structure of the extracellular region of HER3 reveals an interdomain tether. Science (2002) 3.19
Epidermal growth factor receptor dimerization and activation require ligand-induced conformational changes in the dimer interface. Mol Cell Biol (2005) 2.35
Molecular recognition in antibody-antigen complexes. Adv Protein Chem (2002) 2.33
Two EGF molecules contribute additively to stabilization of the EGFR dimer. EMBO J (1997) 2.16
Why the epidermal growth factor receptor? The rationale for cancer therapy. Oncologist (2002) 2.05
Synergistic down-regulation of receptor tyrosine kinases by combinations of mAbs: implications for cancer immunotherapy. Proc Natl Acad Sci U S A (2005) 2.00
Antibody elbow angles are influenced by their light chain class. J Mol Biol (2006) 1.96
Receptor tyrosine kinases: mechanisms of activation and signaling. Curr Opin Cell Biol (2007) 1.96
EGFR targeting of solid tumors. Cancer Control (2007) 1.61
Extracellular domains drive homo- but not hetero-dimerization of erbB receptors. EMBO J (2000) 1.55
Phase I study of the humanized antiepidermal growth factor receptor monoclonal antibody EMD72000 in patients with advanced solid tumors that express the epidermal growth factor receptor. J Clin Oncol (2004) 1.49
Ligand-induced structural transitions in ErbB receptor extracellular domains. Structure (2007) 1.36
Comprehensive functional maps of the antigen-binding site of an anti-ErbB2 antibody obtained with shotgun scanning mutagenesis. J Mol Biol (2002) 1.33
Binding of an antagonistic monoclonal antibody to an intact and fragmented EGF-receptor polypeptide. Arch Biochem Biophys (1987) 1.29
Identification of the epitope for the epidermal growth factor receptor-specific monoclonal antibody 806 reveals that it preferentially recognizes an untethered form of the receptor. J Biol Chem (2004) 1.23
A phase II trial of EMD72000 (matuzumab), a humanized anti-EGFR monoclonal antibody, in patients with platinum-resistant ovarian and primary peritoneal malignancies. Gynecol Oncol (2006) 1.22
Humanization of a mouse monoclonal antibody by CDR-grafting: the importance of framework residues on loop conformation. Protein Eng (1991) 1.18
Phase I study of the humanised anti-EGFR monoclonal antibody matuzumab (EMD 72000) combined with gemcitabine in advanced pancreatic cancer. Br J Cancer (2006) 1.02
A 40-kDa epidermal growth factor/transforming growth factor alpha-binding domain produced by limited proteolysis of the extracellular domain of the epidermal growth factor receptor. J Biol Chem (1993) 1.00
Monoclonal antibody 425 inhibits growth stimulation of carcinoma cells by exogenous EGF and tumor-derived EGF/TGF-alpha. J Cell Biochem (1990) 0.97
Active and inactive conformations of the epidermal growth factor receptor. Biochem Soc Trans (2004) 0.96
Antibodies to the epidermal growth factor receptor in non small cell lung cancer: current status of matuzumab and panitumumab. Clin Cancer Res (2007) 0.87
Clinical trial with escalating doses of the antiepidermal growth factor receptor humanized monoclonal antibody EMD 72 000 in patients with advanced squamous cell carcinoma of the larynx and hypopharynx. Cancer Chemother Pharmacol (2001) 0.83
Distribution of humanized MAb 425 (EMD 62,000) in rats and specific localization in tumor-bearing nude mice. Cell Mol Biol (Noisy-le-grand) (1995) 0.79
An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors. Mol Cell (2003) 5.06
Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. Cancer Cell (2005) 4.73
PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect. Nat Med (2003) 2.97
Epidermal growth factor receptor dimerization and activation require ligand-induced conformational changes in the dimer interface. Mol Cell Biol (2005) 2.35
The extracellular region of ErbB4 adopts a tethered conformation in the absence of ligand. Proc Natl Acad Sci U S A (2005) 1.84
Pleckstrin homology domains and the cytoskeleton. FEBS Lett (2002) 1.71
Golgi localization of glycosyltransferases requires a Vps74p oligomer. Dev Cell (2008) 1.62
PtdIns4P recognition by Vps74/GOLPH3 links PtdIns 4-kinase signaling to retrograde Golgi trafficking. J Cell Biol (2009) 1.58
The EGFR family: not so prototypical receptor tyrosine kinases. Cold Spring Harb Perspect Biol (2014) 1.39
Phosphorylation by casein kinase 2 induces PACS-1 binding of nephrocystin and targeting to cilia. EMBO J (2005) 1.35
Phosphorylation and regulation of a G protein-coupled receptor by protein kinase CK2. J Cell Biol (2007) 1.31
Structural basis for EGF receptor inhibition by the therapeutic antibody IMC-11F8. Structure (2008) 1.26
A biparatopic anti-EGFR nanobody efficiently inhibits solid tumour growth. Int J Cancer (2011) 1.16
Interaction of antibodies with ErbB receptor extracellular regions. Exp Cell Res (2008) 1.13
Closing the yield gap could reduce projected greenhouse gas emissions: a case study of maize production in China. Glob Chang Biol (2013) 1.09
Characterization of c-kit expression in small cell lung cancer: prognostic and therapeutic implications. Clin Cancer Res (2003) 1.09
Lersivirine, a nonnucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus type 1. Antimicrob Agents Chemother (2010) 1.03
Mutation of tyrosine in the conserved NPXXY sequence leads to constitutive phosphorylation and internalization, but not signaling, of the human B2 bradykinin receptor. J Biol Chem (2004) 1.01
Structural evaluation of EGFR inhibition mechanisms for nanobodies/VHH domains. Structure (2013) 1.01
The C-terminal tail of CRTH2 is a key molecular determinant that constrains Galphai and downstream signaling cascade activation. J Biol Chem (2008) 1.01
The tyrosine kinase Pyk2 regulates Arf1 activity by phosphorylation and inhibition of the Arf-GTPase-activating protein ASAP1. J Biol Chem (2003) 0.98
Long-term outcomes of vitrectomy for progressive X-linked retinoschisis. Am J Ophthalmol (2012) 0.95
Protective autophagy is involved in resistance towards MET inhibitors in human gastric adenocarcinoma cells. Biochem Biophys Res Commun (2013) 0.95
Local control of phosphatidylinositol 4-phosphate signaling in the Golgi apparatus by Vps74 and Sac1 phosphoinositide phosphatase. Mol Biol Cell (2012) 0.93
Pellino proteins contain a cryptic FHA domain that mediates interaction with phosphorylated IRAK1. Structure (2008) 0.93
Novel indazole non-nucleoside reverse transcriptase inhibitors using molecular hybridization based on crystallographic overlays. J Med Chem (2009) 0.92
The discovery and optimization of hexahydro-2H-pyrano[3,2-c]quinolines (HHPQs) as potent and selective inhibitors of the mitotic kinesin-5. Bioorg Med Chem Lett (2010) 0.92
Sphingosine 1-phosphate and dioleoylphosphatidic acid are low affinity agonists for the orphan receptor GPR63. Cell Signal (2003) 0.92
Role of the N-terminal extension of the (betaalpha)8-barrel enzyme indole-3-glycerol phosphate synthase for its fold, stability, and catalytic activity. Biochemistry (2005) 0.91
EMD 1214063 and EMD 1204831 constitute a new class of potent and highly selective c-Met inhibitors. Clin Cancer Res (2013) 0.89
Mechanisms for 2-methoxyestradiol-induced apoptosis of prostate cancer cells. FEBS Lett (2002) 0.88
Nephrocystin-4 regulates Pyk2-induced tyrosine phosphorylation of nephrocystin-1 to control targeting to monocilia. J Biol Chem (2011) 0.87
TMP prevents retinal neovascularization and imparts neuroprotection in an oxygen-induced retinopathy model. Invest Ophthalmol Vis Sci (2012) 0.85
Regulated and constitutive activation of specific signalling pathways by the human S1P5 receptor. Br J Pharmacol (2003) 0.85
Nafulsella turpanensis gen. nov., sp. nov., a member of the phylum Bacteroidetes isolated from soil. Int J Syst Evol Microbiol (2012) 0.84
Comparative analysis of functional assays for characterization of agonist ligands at G protein-coupled receptors. J Biomol Screen (2003) 0.80
KH906, a recombinant human VEGF receptor fusion protein, is a new effective topical treatment for corneal neovascularization. Mol Vis (2011) 0.80
A new twist in the transmembrane signaling tool-kit. Cell (2007) 0.79
The pellino e3 ubiquitin ligases recognize specific phosphothreonine motifs and have distinct substrate specificities. Biochemistry (2014) 0.78
Taibaiella smilacinae gen. nov., sp. nov., an endophytic member of the family Chitinophagaceae isolated from the stem of Smilacina japonica, and emended description of Flavihumibacter petaseus. Int J Syst Evol Microbiol (2013) 0.78
Highly selective fluorescent recognition of sulfate in water by two rigid tetrakisimidazolium macrocycles with peripheral chains. J Am Chem Soc (2013) 0.77
The novel ATP-competitive inhibitor of the MET hepatocyte growth factor receptor EMD1214063 displays inhibitory activity against selected MET-mutated variants. Mol Cancer Ther (2013) 0.77
[Effect of plastic film mulching on soil microbial biomass in spring wheat field in semi-arid loess area]. Ying Yong Sheng Tai Xue Bao (2003) 0.75
[Spatial variability of slope land soil solute transport parameters]. Ying Yong Sheng Tai Xue Bao (2005) 0.75
Effects of enhanced atmospheric ammonia on physiological characteristics of maize(Zea mays L.). J Sci Food Agric (2013) 0.75
Transition-metal-free formal decarboxylative coupling of α-oxocarboxylates with α-bromoketones under neutral conditions: a simple access to 1,3-diketones. Angew Chem Int Ed Engl (2014) 0.75
[Effects of irrigation and nitrogen fertilization on winter wheat yield under straw mulch]. Ying Yong Sheng Tai Xue Bao (2005) 0.75
[Effects of plastic film mulching on soil temperature and moisture and on yield formation of spring wheat]. Ying Yong Sheng Tai Xue Bao (2003) 0.75
[Grain-filling characters of different genotype winter wheat under nitrogen fertilization in semi-humid area of south Loess Plateau]. Ying Yong Sheng Tai Xue Bao (2006) 0.75
[Distribution of organic carbon pools in different sizes of soil aggregates in Loess Plateau]. Ying Yong Sheng Tai Xue Bao (2006) 0.75
Assay and functional properties of the tyrosine kinase Pyk2 in regulation of Arf1 through ASAP1 phosphorylation. Methods Enzymol (2005) 0.75